Assessing the Sentimag system for guiding sentinel node biopsies in patients with breast cancer.

INTRODUCTION: Sentinel lymph node biopsy for breast cancer is a method to localize and excise the first draining lymph node from an invasive cancer of the breast. The histopathologic evaluation of the sentinel lymph node is used for predicting recurrence and survival and thus, guiding oncologists for treatment-decision making to administer adjuvant therapies. The ability to identify the sentinel node depends on methods to map lymphatic drainage from the breast to the sentinel node and accurately discriminate that node from other non-sentinel lymph nodes of the axilla. AREAS COVERED: This review covers the clinical demand for technologies to assist the surgeon in intraoperative lymphatic mapping to specifically identify the sentinel lymph node in patients with breast cancer. Performance characteristics are reviewed for superparamagnetic iron oxide tracers used in lymphatic mapping compared to other current available technologies for lymphatic mapping. EXPERT OPINION: The Magtrace (superparamagnetic iron oxide tracer) Sentimag (handheld magnetic probe) system is an FDA-approved technology for intraoperative lymphatic mapping to facilitate sentinel lymph node biopsy in breast cancer with technologic performance characteristics that are equivalent to 99Technetium-sulfur colloid. Barriers to broader utilization primarily center around the need for nonmetallic devices to be used for the conduct of surgery, which would interfere with the paramagnetic method for tracer localization.

Shifting paradigms for the treatment of ductal carcinoma in situ: Less is more.

Ductal carcinoma in situ is a diverse disease in which only 50% of lesions progress to invasive carcinoma, but unfortunately, all patients receive similar treatment recommendations independent of the disease variability. De-escalation is the philosophy that treatment for this disease should be differentiated based on the likelihood of future progression and recurrence. Four surgical trials are looking at the possibility of removing surgical intervention, the current mainstay of treatment, from the algorithm. Molecular assays have been developed to help differentiate the risk of an ipsilateral breast tumor recurrence and potentially guide the postsurgical utility of radiation therapy. Primary endocrine therapy is also being explored as an alternative to standard local therapy. Ductal carcinoma in situ therapy is a very complicated algorithm that should be discussed and treated through shared decision-making.

Early versus delayed appendectomy: A comparison of outcomes.

BACKGROUND: The optimal timing for performing appendectomy in adults remains controversial. METHOD: A one-year retrospective review of adult patients with acute appendicitis who underwent appendectomy. The cohort was divided by time-to-intervention into two groups: patients who underwent appendectomy within 8 h (group 1), and those who had surgery after 8 h (group 2). Outcome measures including perioperative morbidity and mortality, post-operative length of stay, and the 30-day readmission rate were compared between the two groups. RESULTS: A total of 116 patients who underwent appendectomy met the inclusion criteria: 75 patients (65%) in group 1, and 41 (35%) in group 2. There were no differences between group 1 & 2 in perioperative complications (6.7% vs. 9.8%, P = 0.483), postoperative length of stay (median [IQR]; 19.5 [11.5-40.5] vs. 20.0 [11.25-58.5] hours, P = 0.632), or 30-day readmission rate (2.7% vs. 4.9%, P = 0.543). There were no deaths in either group. CONCLUSION: Delayed appendectomy performed more than 8 h was not associated with increased perioperative complications, postoperative length of stay, 30-day readmission rate, or mortality.